Home » Newsletters » BioWorld

BioWorld

May 25, 2006

View Archived Issues

Sirna Brings In $45M Publicly; Lead Drug Aimed For Phase II

Sirna Therapeutics Inc. bolstered its bank account with a $45 million financing that closed Wednesday. (BioWorld Today) Read More

CareX Purchase Expands 7TM's Early Stage Metabolic Pipeline

Ocera's AST-120 In Phase III Trial For Fistulizing Crohn's

Aphton Bankruptcy News Blasts Stock; Igeneon Also Facing Risk

Other News To Note

Appointments And Advancements

Clinic Roundup

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...